A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of Mrna-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors (Keynote-603).
Journal of Global Oncology(2019)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined